This is a StreetInsider.com Premium Only Page

Humanigen Inc. (HGEN) – Globe Newswire

Oct 21, 2022 09:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm

Oct 16, 2022 11:24 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm

Oct 11, 2022 10:05 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm

Oct 6, 2022 09:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stitch Fix, Coupang, Humanigen, and Latch and Encourages Investors to Contact the Firm

Oct 2, 2022 09:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stitch Fix, Coupang, Humanigen, and Latch and Encourages Investors to Contact the Firm

Sep 26, 2022 09:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm

Sep 21, 2022 09:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm

Sep 16, 2022 09:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Stitch Fix, Coupang, Humanigen, and Latch and Encourages Investors to Contact the Firm

Sep 11, 2022 09:00 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coupang, Humanigen, Latch, and Azure and Encourages Investors to Contact the Firm

Sep 6, 2022 10:17 PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Humanigen, and Kohl’s and Encourages Investors to Contact the Firm

Aug 10, 2022 04:50 PM Aquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy Space

Jul 26, 2021 08:00 AM Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development

Jul 26, 2021 08:00 AM Ensysce Biosciences Bolsters Management Team with Appointments of David J. Kovacs as VP Public Policy and David Tanzer as VP Strategic Development

Feb 3, 2021 07:00 AM Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

Oct 15, 2019 08:00 AM Humanigen Announces Exploration of Potential Rights Offering

Oct 8, 2019 08:00 AM New ‘Blood Advances®’ Publication Supports Humanigen’s GM-CSF Neutralization Strategy with Lenzilumab in GvHD

Oct 7, 2019 08:00 AM Humanigen, Inc. to Webcast Live at VirtualInvestorConferences.com October 10th